Among 9 analysts covering Nuvista Energy Ltd. (TSE:NVA), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Nuvista Energy Ltd. had 41 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of NuVista Energy Ltd. (TSE:NVA) has “Outperform” rating given on Wednesday, January 18 by RBC Capital Markets. The firm earned “Outperform” rating on Monday, October 31 by RBC Capital Markets. The rating was maintained by TD Securities on Wednesday, January 18 with “Buy”. Scotia Capital maintained the shares of NVA in report on Thursday, August 11 with “Outperform” rating. The firm has “Buy” rating by TD Securities given on Friday, August 12. TD Securities maintained NuVista Energy Ltd. (TSE:NVA) on Wednesday, August 12 with “Buy” rating. National Bank Canada upgraded NuVista Energy Ltd. (TSE:NVA) on Thursday, February 2 to “Outperform” rating. Raymond James maintained NuVista Energy Ltd. (TSE:NVA) on Monday, June 6 with “” rating. The rating was maintained by Scotia Capital on Tuesday, January 17 with “Outperform”. On Friday, February 12 the stock rating was initiated by BMO Capital Markets with “Market Perform”. See NuVista Energy Ltd. (TSE:NVA) latest ratings:
01/11/2017 Broker: BMO Capital Markets Rating: Market Perform Old Target: $8.00 New Target: $9.00 Target Up
01/11/2017 Broker: Eight Capital Old Rating: Neutral New Rating: Buy Old Target: $9.00 New Target: $10.25 Upgrade
01/11/2017 Broker: Raymond James Old Rating: Outperform New Rating: Strong Buy Old Target: $9.25 New Target: $11.00 Downgrade
01/11/2017 Broker: RBC Capital Markets Rating: Outperform Old Target: $9.00 New Target: $10.00 Target Down
CHIEF FINANCIAL OFFICER Craig Tooman of Aratana Therapeutics Inc, sold 30,000 of the Pinksheet-listed Aratana Therapeutics Inc shares valued at $158,040 U.S. Dollars with an average of $5.3 per share price. Craig Tooman now possess 0.17% of the Company’s total market cap with ownership of 75,024 shares.
The stock increased 4.40% or $0.36 during the last trading session, reaching $8.55. About 634,532 shares traded or 40.44% up from the average. NuVista Energy Ltd. (TSE:NVA) has 0.00% since January 13, 2017 and is . It has underperformed by 16.70% the S&P500.
NuVista Energy Ltd., an oil and natural gas company, explores for, develops, and produces oil and natural gas reserves in Canada. The company has market cap of $1.48 billion. It primarily focuses on the condensate-rich Montney formation in the Wapiti area of the Alberta Deep Basin. It has a 24.29 P/E ratio.
Analysts await Aratana Therapeutics, Inc. (NASDAQ:PETX) to report earnings on March, 12. They expect $-0.23 EPS, up 34.29% or $0.12 from last year’s $-0.35 per share. After $-0.21 actual EPS reported by Aratana Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 9.52% negative EPS growth.
Since September 15, 2017, it had 0 insider purchases, and 3 sales for $435,742 activity. Standridge Brent sold 10,000 shares worth $61,127. On Friday, September 15 HEINEN ERNST sold $62,500 worth of Aratana Therapeutics, Inc. (NASDAQ:PETX) or 10,000 shares. St Peter Steven had sold 50,000 shares worth $312,115.
Among 8 analysts covering Aratana Therapeutics (NASDAQ:PETX), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Aratana Therapeutics has $28 highest and $6.0 lowest target. $13.08’s average target is 150.57% above currents $5.22 stock price. Aratana Therapeutics had 17 analyst reports since July 29, 2015 according to SRatingsIntel. Jefferies initiated the shares of PETX in report on Friday, August 19 with “Buy” rating. The stock of Aratana Therapeutics, Inc. (NASDAQ:PETX) has “Buy” rating given on Wednesday, November 15 by Jefferies. The company was initiated on Thursday, February 4 by Credit Suisse. The firm earned “Buy” rating on Wednesday, July 29 by Lake Street. On Friday, November 3 the stock rating was maintained by Jefferies with “Buy”. The stock of Aratana Therapeutics, Inc. (NASDAQ:PETX) has “Hold” rating given on Monday, October 23 by Stifel Nicolaus. The stock of Aratana Therapeutics, Inc. (NASDAQ:PETX) earned “Overweight” rating by Barclays Capital on Thursday, August 11. Jefferies maintained Aratana Therapeutics, Inc. (NASDAQ:PETX) rating on Friday, August 4. Jefferies has “Buy” rating and $800 target. The rating was downgraded by Craig Hallum to “Hold” on Friday, September 25. Stifel Nicolaus maintained Aratana Therapeutics, Inc. (NASDAQ:PETX) rating on Wednesday, March 16. Stifel Nicolaus has “Buy” rating and $11 target.
Investors sentiment decreased to 1.72 in 2017 Q3. Its down 0.80, from 2.52 in 2017Q2. It worsened, as 12 investors sold Aratana Therapeutics, Inc. shares while 13 reduced holdings. 9 funds opened positions while 34 raised stakes. 31.53 million shares or 1.39% more from 31.10 million shares in 2017Q2 were reported. Bank & Trust Of Montreal Can stated it has 15,172 shares. Vanguard Gru holds 0% or 1.74M shares in its portfolio. Stifel accumulated 14,300 shares. Fny Managed Accounts Ltd Liability owns 2,000 shares or 0.02% of their US portfolio. Blackrock holds 3.11 million shares or 0% of its portfolio. Jpmorgan Chase Commerce accumulated 0% or 128 shares. Proshare Advsrs Lc has invested 0% of its portfolio in Aratana Therapeutics, Inc. (NASDAQ:PETX). Raymond James Advsr Incorporated has invested 0% of its portfolio in Aratana Therapeutics, Inc. (NASDAQ:PETX). Redmond Asset Management Ltd Co reported 55,941 shares or 0.16% of all its holdings. Blair William Il has invested 0.04% in Aratana Therapeutics, Inc. (NASDAQ:PETX). Wells Fargo Mn reported 367,365 shares. Hutchin Hill Cap Lp accumulated 21,300 shares. Dimensional Fund Advisors Ltd Partnership holds 0% or 388,437 shares in its portfolio. Ameritas Inv Prns reported 3,555 shares. Bancorp Of Ny Mellon reported 0% of its portfolio in Aratana Therapeutics, Inc. (NASDAQ:PETX).
Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. The company has market cap of $224.46 million. The Company’s product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. It currently has negative earnings. The firm markets GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; ENTYCE for appetite stimulation in dogs; and NOCITA, a post-operative anesthetic for cranial cruciate ligament surgery in dogs.